Allergy and Immunology · Acquired Angioedema with C1 Inhibitor Deficiency

Managing Attacks and Preventing Future Swelling

At a Glance

AAE-C1-INH attacks are bradykinin-driven, so allergy medicines such as epinephrine and antihistamines do not treat them. Patients need a specialist-directed rescue plan, individualized prevention, medication review, and advance planning for dental or surgical procedures.

Because Acquired Angioedema with C1 Inhibitor Deficiency (AAE-C1-INH) is a bradykinin-mediated condition, managing it requires a different strategy than treating allergies ^[1]. Your care plan involves two main goals: stopping an active attack as quickly as possible (acute treatment) and, if attacks are frequent, reducing how often they happen (prophylaxis) ^[2].

Travel and Rescue Kit Checklist

Adequate prescription supply.
Expiration dates checked.
Safe storage maintained.
Injection training completed.
Medical-alert card and treatment plan copies available.

Stopping an Active Attack

When an attack begins, the goal is to intervene before the swelling becomes severe or affects your airway. Unlike allergies, these attacks do not respond to epinephrine or antihistamines ^[3]. Many of these therapies are approved for Hereditary Angioedema (HAE) and their use in AAE is off-label and specialist-directed.

Targeted Therapies

Plasma-Derived C1-INH Concentrate (pdC1-INH): This medicine replaces the protein your body is missing or consuming ^[4]. In a large study, it was effective in over 97% of attacks ^[4]. However, if you have autoantibodies that attack C1-INH, you may need a much higher dose to stop the swelling—sometimes more than double the standard dose. Do not repeat or increase doses without a written plan ^[4]^[5].
Icatibant: This is a subcutaneous (under the skin) injection that blocks bradykinin from attaching to your blood vessels ^[6]. It is often used as a backup if C1-INH replacement doesn’t work, particularly for patients with high levels of autoantibodies ^[7]^[6].
Ecallantide: This is another specialist-administered injection that stops the enzyme (kallikrein) from producing bradykinin in the first place, but it carries a risk of hypersensitivity/anaphylaxis ^[6].

Long-Term Prevention (Prophylaxis)

If your attacks are frequent, severe, or occur in dangerous areas like the throat, your doctor may suggest daily medication to prevent them ^[2]. Evidence for long-term prophylaxis in AAE is limited and individualized.

Medication Options

Tranexamic Acid: This is an “antifibrinolytic” that helps stabilize the contact system ^[2]. While often effective, it carries a risk of thrombosis (blood clots) and requires assessment for contraindications ^[8]^[2].
Attenuated Androgens (like Danazol): These are synthetic hormones that can prompt your body to produce more C1-INH ^[9]. Because these are often used in older adults with AAE, doctors must carefully monitor for side effects, including liver toxicity, high blood pressure, and changes in cardiovascular risk ^[10]^[11].

Note: The most effective way to prevent AAE attacks is often to treat the underlying condition, such as a B-cell disorder or MGUS, that is causing the deficiency in the first place ^[12]^[13].

Medication Safety and Red Flags

Certain medications that are common for other adult health conditions can be dangerous if you have AAE-C1-INH.

The ACE Inhibitor Danger

ACE inhibitors are common blood pressure medications (names usually end in -pril, like lisinopril or enalapril) ^[14]. They work by blocking an enzyme that normally breaks down bradykinin. ACE inhibitors are generally avoided because they can precipitate or worsen bradykinin-mediated angioedema ^[15]^[16]. It is vital that you do not stop or substitute blood-pressure treatment on your own; contact your prescriber promptly to discuss a safe transition.

Other Medications to Discuss

ARBs: Some blood pressure medicines ending in -sartan (like losartan) have also been linked to angioedema and require individualized risk assessment ^[17].
DPP-4 Inhibitors: Certain diabetes medications (like sitagliptin) may increase the risk of swelling and should be reviewed ^[18].

Planning for Procedures and Dental Work

Minor trauma, especially in the mouth or throat (like a dental cleaning or tooth extraction), is a known trigger for AAE attacks ^[19].

Before any medical or dental procedure, you must have a multidisciplinary plan ^[19]:

Short-Term Prophylaxis: Prophylaxis is risk-based rather than automatic for every procedure, determined by specialist assessment ^[20].
Rescue Readiness: You should have acute rescue medication (like icatibant or C1-INH) immediately available at the site of the procedure ^[19].
Observation: Because swelling can sometimes start several hours after a procedure, you may need to be monitored closely during recovery ^[21].

Common questions in this guide

How are active attacks of acquired angioedema treated?

Active AAE-C1-INH attacks are treated with specialist-directed medicines such as plasma-derived C1-INH concentrate, icatibant, or ecallantide. Because the swelling is driven by bradykinin rather than an allergy, epinephrine and antihistamines do not treat these attacks.

What if C1-INH concentrate does not stop my swelling?

C1-INH autoantibodies can make replacement treatment less effective, and some people may need a higher dose. Never repeat or increase a dose without a written plan; your specialist may prescribe icatibant as a backup, especially when autoantibodies are present.

When might I need daily prevention for AAE-C1-INH?

Daily prophylaxis may be considered when attacks are frequent, severe, or involve the throat. Tranexamic acid and attenuated androgens such as danazol are options, but treatment is individualized because of risks such as blood clots, liver toxicity, high blood pressure, and cardiovascular effects. Evidence for long-term prevention in acquired angioedema is limited.

Which medicines can worsen acquired angioedema?

ACE inhibitors, whose names often end in -pril, can trigger or worsen bradykinin-mediated swelling and are generally avoided in AAE-C1-INH. Some ARBs ending in -sartan and DPP-4 diabetes medicines may also raise risk, so review all medicines with your prescriber and do not stop blood-pressure treatment yourself.

How should I prepare for dental work or surgery?

Dental work and surgery can cause mouth or throat trauma that triggers an attack, sometimes hours later. Before a procedure, a specialist should decide whether short-term prevention is needed, ensure rescue medicine is immediately available, and plan close observation.

What should I keep in an acquired angioedema rescue kit?

Keep enough prescribed medicine, check expiration dates, store it safely, and complete injection training if applicable. Carry a medical-alert card and copies of your treatment plan, and make sure trusted people know how to help.

Can treating an underlying blood disorder reduce my attacks?

Treating an underlying B-cell disorder or MGUS may reduce the cause of C1-INH deficiency and can be an important part of preventing attacks. Whether angioedema medicines can be reduced or stopped depends on your response and must be decided by your treating specialists.

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Acquired angioedema with C1Inh deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Curated prompts to bring to your next appointment.

1.Do I have anti-C1-INH autoantibodies, and does that mean I should have a higher starting dose of C1 inhibitor concentrate?
2.If my first dose of C1 inhibitor doesn't stop an attack, how long should I wait before using a backup medicine like icatibant?
3.Given my age and health history, what are the specific risks for me if we start long-term prophylaxis with danazol or tranexamic acid?
4.What is our specific plan for my upcoming dental or surgical procedure? When exactly should I receive prophylaxis?
5.I'm taking several other medications; are there any known interactions between my current pills and the ones we are considering for AAE?
6.Since we've identified an underlying blood disorder, will treating that make these angioedema medications more effective or even unnecessary?

Key takeaways

AAE-C1-INH attacks require targeted, specialist-directed medicines such as plasma-derived C1-INH concentrate, icatibant, or ecallantide; epinephrine and antihistamines do not treat these attacks.
Frequent, severe, or throat attacks may warrant individualized prophylaxis with medicines such as tranexamic acid or danazol, balanced against their risks.
ACE inhibitors ending in -pril can trigger or worsen bradykinin-mediated swelling, so blood-pressure medicines should be reviewed promptly with the prescriber rather than stopped independently.
Dental and surgical procedures can trigger delayed swelling, so patients need risk-based prophylaxis, rescue medication available at the site, and appropriate observation.
Treating an underlying B-cell disorder or MGUS may be central to reducing acquired angioedema attacks.

References (21)

1
Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.
Zeerleder S, Levi M
Annals of medicine 2016; (48(4)):256-67 doi:10.3109/07853890.2016.1162909.
PMID: 27018196
2
[Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment].
Gobert D, Bouillet L, Armengol G, et al.
La Revue de medecine interne 2020; (41(12)):838-842 doi:10.1016/j.revmed.2020.06.010.
PMID: 32753245
3
Resolution of Laryngeal Oedema in a Patient with Acquired C1-Inhibitor Deficiency. a Case Report.
Bara NA, Nadasan V
Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) 2021; (7(2)):136-140 doi:10.2478/jccm-2021-0003.
PMID: 34722915
4
Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.
Bork K, Staubach-Renz P, Hardt J
Orphanet journal of rare diseases 2019; (14(1)):65 doi:10.1186/s13023-019-1043-3.
PMID: 30866985
5
Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency.
Zanichelli A, Azin GM, Wu MA, et al.
The journal of allergy and clinical immunology. In practice 2017; (5(5)):1307-1313 doi:10.1016/j.jaip.2016.12.032.
PMID: 28284781
6
Acquired angioedema in B cell lymphoproliferative disease: A retrospective case series.
Wonnaparhown A, Stefanovic A, Lugar P, Hostetler HP
Clinical and experimental immunology 2021; (206(3)):378-383 doi:10.1111/cei.13667.
PMID: 34586637
7
Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features, and Management: A Nationwide Retrospective Study in the Czech Republic Patients.
Sobotkova M, Zachova R, Hakl R, et al.
International archives of allergy and immunology 2021; (182(7)):642-649 doi:10.1159/000512933.
PMID: 33472202
8
Longitudinal experience with treatment of acquired angioedema using tranexamic acid.
Kesh S, Singh U, Bernstein JA
Allergy and asthma proceedings 2022; (43(5)):413-418 doi:10.2500/aap.2022.43.220043.
PMID: 36065111
9
Nine year follow-up of a rare case of angioedema due to acquired C1-inhibitor deficiency with late onset and good response to attenuated androgen.
Leru PM, Anton VF, Bumbea H
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2018; (14()):69 doi:10.1186/s13223-018-0274-5.
PMID: 30386386
10
Comorbidities in Angioedema Due to C1-Inhibitor Deficiency: An Italian Survey.
Zanichelli A, Senter R, Merlo A, et al.
The journal of allergy and clinical immunology. In practice 2024; (12(4)):1029-1036 doi:10.1016/j.jaip.2023.12.046.
PMID: 38182098
11
Anabolic androgen use in the management of hereditary angioedema: Not so cheap after all.
Tse KY, Zuraw BL, Chen Q, Christiansen SC
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2017; (118(4)):456-460.e1 doi:10.1016/j.anai.2017.01.015.
PMID: 28283277
12
A multi-centre UK-based survey on angioedema secondary to acquired C1 inhibitor deficiency.
Morsi H, Huissoon A, Grammatikos A, et al.
Clinical and experimental immunology 2025; (219(1)) doi:10.1093/cei/uxae121.
PMID: 39756409
13
Angioedema due to Acquired C1-Inhibitor Deficiency Associated With Monoclonal Gammopathies of Undetermined Significance Characteristics of a French National Cohort.
Lahuna C, Defendi F, Bouillet L, et al.
The journal of allergy and clinical immunology. In practice 2024; (12(12)):3283-3291 doi:10.1016/j.jaip.2024.09.016.
PMID: 39357560
14
A follow-up survey of patients with acquired angioedema due to C1-inhibitor deficiency.
Pólai Z, Balla Z, Andrási N, et al.
Journal of internal medicine 2021; (289(4)):547-558 doi:10.1111/joim.13182.
PMID: 33215769
15
Angioedema Shortly After Adding Empagliflozin to Losartan.
Duodu P, Aiad M, Deeb M, et al.
Cureus 2025; (17(1)):e78033 doi:10.7759/cureus.78033.
PMID: 40013202
16
A Rare Case Report of Sitagliptin-Induced Angioedema.
Sharma NR, Sharma B, Lamichhane S, et al.
Cureus 2022; (14(10)):e30077 doi:10.7759/cureus.30077.
PMID: 36381841
17
[Acquired C1 esterase inhibitor deficiency via bradykinin-mediated angioedema: Four cases].
Jacquin-Porretaz C, Castelain F, Daguindau E, et al.
Annales de dermatologie et de venereologie 2018; (145(10)):598-602 doi:10.1016/j.annder.2018.02.012.
PMID: 29673745
18
Bradykinin-Mediated Angioedema Induced by Drugs.
Suffritti C, Chan S, Ferrara AL, et al.
Journal of clinical medicine 2025; (14(16)) doi:10.3390/jcm14165712.
PMID: 40869540
19
Anesthetic management of a patient with acquired angioedema submitted to broncofibroscopy: a case report.
Barata M, Marques A, Tiago C, et al.
Brazilian journal of anesthesiology (Elsevier) 2023; (73(4)):500-502 doi:10.1016/j.bjane.2021.11.007.
PMID: 34848320
20
Perioperative management for patients with hereditary angioedema.
Williams AH, Craig TJ
Allergy & rhinology (Providence, R.I.) 2015; (6(1)):50-5 doi:10.2500/ar.2015.6.0112.
PMID: 25860171
21
Perioperative course in patients with hereditary or acquired angioedema.
MacBeth LS, Volcheck GW, Sprung J, Weingarten TN
Journal of clinical anesthesia 2016; (34()):385-91.
PMID: 27687418

This page is for informational purposes only and does not constitute medical advice. A specialist should individualize your rescue, prevention, medication-safety, and procedure plan for AAE-C1-INH.

Guide Contents